Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  St. Jude Medical, Inc.    STJ

Delayed Quote. Delayed  - 09/28 03:35:32 pm
79.76 USD   +0.20%
09/21 Intermountain Healthcare Announces 2016 Supplier Award Winners
09/21 CONSTANT MOVEME : Valeant Pharmaceuticals International, Inc. St. J..
09/17DJJ&J to Buy Abbott Eye Business -- WSJ
News SummaryMost relevantAll newsSector news 

St. Jude Medical, Inc. : St Jude To Stop Selling Another Version Of Defibrillator Wires

share with twitter share with LinkedIn share with facebook
share via e-mail
04/04/2012 | 03:48pm CEST

St. Jude Medical Inc. (STJ) will stop selling another version of its defibrillator wires in an effort to head off potential problems like those the medical-device maker is currently battling with its Riata and Riata ST wires.

The Riata defibrillator wires, called leads, are no longer on the market but are still implanted in thousands of patients in the U.S. In a medical journal last month, prominent cardiologist Robert G. Hauser wrote that the cables are responsible for at least 20 deaths.

Wednesday, the company said it will cease selling its QuickSite and QuickFlex left-ventricular leads used to connect cardiac resynchronization therapy devices to the heart. Roughly 171,000 QuickSite and QuickFlex leads have been sold worldwide.

The decision comes as St. Jude has confirmed 39 cases of the metal wires wearing through their silicone covering, leading to an incidence rate of 2.3 in every 10,000 leads. Still, it stressed that its decision to stop selling the wires is a proactive one.

"It is important to note, however, that the overall safety and reliability of QuickSite and QuickFlex leads continues to be comparable to currently available CRT leads from other manufacturers," the company wrote.

The wire leads connect life-saving medical devices, which are placed under the skin in the shoulder area, to the heart and delivers a jolt that restores proper rhythm. Because of the constant pounding motion of the heart, the thin leads can be damaged.

Shares closed Tuesday at $43.80 and were inactive in premarket trading. The stock is up roughly 36% from lows hit late last year when the Food and Drug Administration termed the Riata defibrillator issues as a Class I recall, which applies to grave dangers like chance of death.

   -By Mia Lamar, Dow Jones Newswires; 212-416-3207; mia.lamar@dowjones.com 

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ST. JUDE MEDICAL, INC.
09/23 ST JUDE MEDICAL : Special Notice - Curved Cannulas for Neurotherm RFA machine
09/21 Intermountain Healthcare Announces 2016 Supplier Award Winners
09/21 CONSTANT MOVEMENTS OF STOCKS : Valeant Pharmaceuticals International, Inc. St. ..
09/21 SPECIAL NOTICE - INTENT TO SOLE SOUR : St. Jude Medical, Inc.
09/21 ST JUDE MEDICAL : Assigned Patent
09/17DJJ&J to Buy Abbott Eye Business -- WSJ
09/16DJJ&J to Buy Abbott's Eye-Surgery Unit for $4.325 billion -- 2nd Update
09/16DJJ&J to Buy Abbott's Eye-Surgery Unit for $4.325 billion -- 3rd Update
09/16DJJ&J to Buy Abbott's Eye-Surgery Unit for $4.325 billion -- Update
09/16DJJ&J Nears Deal to buy Abbott's Eye-Surgery Equipment Unit
More news
Sector news : Medical Devices & Implants
08/26DJMEDTRONIC : Files 8K - Increased Financial Obligation
08/25DJMEDTRONIC : Profit Rises, Helped by Lower Expenses
08/10 FTSE notches up fifth day of gains on firm financials
08/04 Business groups sue over new U.S. limit on tax-driven foreign buyouts
08/04DJBECTON DICKINSON : Tops Earnings Views, Cuts Revenue Guidance
More sector news : Medical Devices & Implants
News from SeekingAlpha
09/21 Presenting Apple's First Car
09/18 Abbott Laboratories - Reducing Leverage And Increasing Focus Following Vision..
09/14 Will The Market Catch Hillary's Bug?
09/08 Google Enters New Era
09/07 Bank Of America M&A Imminent
Financials ($)
Sales 2016 6 052 M
EBIT 2016 1 513 M
Net income 2016 934 M
Debt 2016 4 898 M
Yield 2016 1,46%
P/E ratio 2016 24,94
P/E ratio 2017 20,48
EV / Sales 2016 4,57x
EV / Sales 2017 4,19x
Capitalization 22 769 M
More Financials
Duration : Period :
St. Jude Medical, Inc. Technical Analysis Chart | STJ | US7908491035 | 4-Traders
Full-screen chart
Technical analysis trends ST. JUDE MEDICAL,...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 21
Average target price 79,7 $
Spread / Average Target -0,26%
Consensus details
EPS Revisions
More Estimates Revisions
Michael T. Rousseau President, Chief Executive Officer & Director
Daniel J. Starks Executive Chairman
Scott P. Thome Vice President-Global Operations & Supply Chain
Donald J. Zurbay Chief Financial Officer & Vice President
Mark D. Carlson Chief Medical Officer & VP-Global Clinical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ST. JUDE MEDICAL, INC.29.37%22 527
SMITH & NEPHEW PLC2.65%14 247
GLAUKOS CORP59.01%1 263
ENDOLOGIX, INC.30.51%1 049
More Results